These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

65 related items for PubMed ID: 3810553

  • 1. Studies on production of antithrombin III with special reference to endotoxin-induced DIC in dogs.
    Tanaka H, Kobayashi N, Maekawa T.
    Thromb Haemost; 1986 Oct 21; 56(2):137-43. PubMed ID: 3810553
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Effect of heparin and/or antithrombin III in a model of disseminated intravascular coagulation induced by endotoxin in rabbits].
    Gómez C, Páramo JA, Rocha E.
    Sangre (Barc); 1992 Feb 21; 37(1):5-10. PubMed ID: 1585238
    [Abstract] [Full Text] [Related]

  • 4. Endotoxin-induced intravascular coagulation (DIC) and its therapy.
    Prager RL, Dunn EL, Kirsh MM, Penner JA.
    Adv Shock Res; 1979 Feb 21; 2():277-87. PubMed ID: 400581
    [Abstract] [Full Text] [Related]

  • 5. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin.
    Triantaphyllopoulos DC.
    Thromb Haemost; 1984 Apr 30; 51(2):232-5. PubMed ID: 6377565
    [Abstract] [Full Text] [Related]

  • 6. Human antithrombin concentrates and experimental disseminated intravascular coagulation.
    Mammen EF, Miyakawa T, Phillips TF, Assarian GS, Brown JM, Murano G.
    Semin Thromb Hemost; 1985 Oct 30; 11(4):373-83. PubMed ID: 4071063
    [Abstract] [Full Text] [Related]

  • 7. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits.
    Bregengård C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V.
    Blood Coagul Fibrinolysis; 1993 Oct 30; 4(5):699-706. PubMed ID: 8292719
    [Abstract] [Full Text] [Related]

  • 8. Diagnosis of disseminated intravascular coagulation in dogs admitted to an intensive care unit.
    Bateman SW, Mathews KA, Abrams-Ogg AC, Lumsden JH, Johnstone IB, Hillers TK, Foster RA.
    J Am Vet Med Assoc; 1999 Sep 15; 215(6):798-804. PubMed ID: 10496131
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Fundamental studies on the management of disseminated intravascular coagulation (DIC) with antithrombin III (AT-III) concentrate].
    Gotoh K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Apr 15; 37(4):571-80. PubMed ID: 3989338
    [Abstract] [Full Text] [Related]

  • 11. Short-time rabbit model of endotoxin-induced hypercoagulability.
    Scherer RU, Giebler RM, Schmidt U, Paar D, Wüst T, Spangenberg P, Militzer K, Hirche H, Kox WJ.
    Lab Anim Sci; 1995 Oct 15; 45(5):538-46. PubMed ID: 8569153
    [Abstract] [Full Text] [Related]

  • 12. Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide-induced DIC models in rats.
    Asakura H, Suga Y, Yoshida T, Ontachi Y, Mizutani T, Kato M, Ito T, Morishita E, Yamazaki M, Miyamoto K, Nakao S.
    Blood Coagul Fibrinolysis; 2003 Apr 15; 14(3):221-8. PubMed ID: 12695743
    [Abstract] [Full Text] [Related]

  • 13. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III.
    Aoki Y, Ohishi R, Takei R, Matsuzaki O, Mohri M, Saitoh K, Gomi K, Sugihara T, Kiyota T, Yamamoto S.
    Thromb Haemost; 1994 Apr 15; 71(4):452-5. PubMed ID: 8052962
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study.
    Aibiki M, Fukuoka N, Nishiyama T, Maekawa S, Shirakawa Y.
    Shock; 2007 Aug 15; 28(2):141-7. PubMed ID: 17515857
    [Abstract] [Full Text] [Related]

  • 16. Heparin-enhanced inhibitors during reversible disseminated intravascular coagulation.
    Marbet GA, Griffith MJ, Roberts HR.
    Scand J Clin Lab Invest Suppl; 1985 Aug 15; 178():95-8. PubMed ID: 3867125
    [Abstract] [Full Text] [Related]

  • 17. [Antithrombin III substitution in patients in shock].
    Vinazzer H, Blauhut B, Bergmann H.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984 Aug 15; 111(6):806-16. PubMed ID: 6083957
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced acute disseminated intravascular coagulation.
    Mischke R, Fehr M, Nolte I.
    Res Vet Sci; 2005 Aug 15; 79(1):69-76. PubMed ID: 15894027
    [Abstract] [Full Text] [Related]

  • 19. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
    Tran TH, Duckert F.
    Thromb Haemost; 1984 Oct 31; 52(2):112-6. PubMed ID: 6395434
    [Abstract] [Full Text] [Related]

  • 20. The effect of prophylactic heparinization on DIC arising from transitory circulatory arrest in dogs.
    Takemoto Y, Tanabe J, Tanaka S, Fukuda A, Fujii C, Kohama A, Shibata S.
    Circ Shock; 1985 Oct 31; 15(2):131-9. PubMed ID: 3978765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.